Logo

CELG-RI

Bristol-Myers Squibb Company Ce

CELG-RI

Bristol-Myers Squibb Company Ce • NYSE
$0.03 ▲ 2.31% (+0.00)
Market Cap $90.01 B
52w High $0.03
52w Low $0.03
Dividend Yield 0%
P/E 0
Volume 11.64K
Outstanding Shares 3383.91B

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $12.222B ▼ $4.221B ▲ $2.201B ▲ 18.009% ▲ $1.08 ▲ $4.62B ▲
Q2-2025 $12.269B ▲ $3.953B ▲ $1.31B ▼ 10.677% ▼ $0.64 ▼ $3.287B ▼
Q1-2025 $11.201B ▼ $3.819B ▼ $2.456B ▲ 21.927% ▲ $1.21 ▲ $4.492B ▲
Q4-2024 $12.342B ▲ $4.893B ▲ $72M ▼ 0.583% ▼ $0.035 ▼ $2.54B ▼
Q3-2024 $11.892B $4.357B $1.211B 10.183% $0.6 $4.773B

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $16.502B ▲ $96.889B ▲ $78.289B ▲ $18.552B ▲
Q2-2025 $13.617B ▲ $94.676B ▲ $77.186B ▲ $17.436B ▲
Q1-2025 $11.782B ▲ $92.427B ▼ $74.979B ▼ $17.389B ▲
Q4-2024 $10.859B ▲ $92.603B ▼ $76.215B ▼ $16.335B ▼
Q3-2024 $8.094B $93.67B $76.47B $17.142B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $2.195B ▲ $6.311B ▲ $-1.702B ▼ $-1.49B ▲ $3.115B ▲ $5.991B ▲
Q2-2025 $1.313B ▼ $3.917B ▲ $-473M ▲ $-1.836B ▼ $1.736B ▲ $3.556B ▲
Q1-2025 $2.456B ▲ $1.954B ▼ $-499M ▼ $-993M ▲ $528M ▼ $1.694B ▼
Q4-2024 $76M ▼ $4.439B ▼ $-196M ▲ $-1.642B ▲ $2.454B ▲ $4.061B ▼
Q3-2024 $1.215B $5.591B $-219M $-3.852B $1.598B $5.267B

Revenue by Products

Product Q2-2024Q3-2024Q4-2024Q1-2025
Abecma
Abecma
 $100.00M ▲$120.00M ▲$100.00M ▼$100.00M ▲
Abraxane
Abraxane
 $230.00M ▲$250.00M ▲$170.00M ▼$100.00M ▼
Breyanzi
Breyanzi
 $150.00M ▲$220.00M ▲$260.00M ▲$260.00M ▲
Camzyos
Camzyos
 $140.00M ▲$160.00M ▲$220.00M ▲$160.00M ▼
Cobenfy
Cobenfy
 $0 ▲$0 ▲$0 ▲$30.00M ▲
Eliquis
Eliquis
 $3.42Bn ▲$3.00Bn ▼$3.19Bn ▲$3.56Bn ▲
Krazati
Krazati
 $30.00M ▲$30.00M ▲$40.00M ▲$50.00M ▲
Opdivo
Opdivo
 $2.39Bn ▲$2.36Bn ▼$2.48Bn ▲$2.27Bn ▼
Opdivo Ovantig
Opdivo Ovantig
 $0 ▲$0 ▲$0 ▲$10.00M ▲
Opdualag
Opdualag
 $230.00M ▲$230.00M ▲$250.00M ▲$250.00M ▲
Orencia
Orencia
 $950.00M ▲$940.00M ▼$1.00Bn ▲$770.00M ▼
Other Growth Brands
Other Growth Brands
 $340.00M ▲$430.00M ▲$510.00M ▲$400.00M ▼
Other Legacy Brands
Other Legacy Brands
 $220.00M ▲$230.00M ▲$250.00M ▲$200.00M ▼
PomalystImnovid
PomalystImnovid
 $960.00M ▲$900.00M ▼$820.00M ▼$660.00M ▼
Reblozyl
Reblozyl
 $420.00M ▲$450.00M ▲$550.00M ▲$480.00M ▼
Revlimid
Revlimid
 $1.35Bn ▲$1.41Bn ▲$1.34Bn ▼$940.00M ▼
Sotyktu
Sotyktu
 $50.00M ▲$70.00M ▲$80.00M ▲$60.00M ▼
Sprycel
Sprycel
 $420.00M ▲$290.00M ▼$200.00M ▼$170.00M ▼
Yervoy
Yervoy
 $630.00M ▲$640.00M ▲$680.00M ▲$620.00M ▼
Zeposia
Zeposia
 $150.00M ▲$150.00M ▲$160.00M ▲$110.00M ▼

Five-Year Company Overview

Income Statement

Income Statement Revenue has grown steadily over the past several years, showing that the underlying business continues to expand despite patent pressures and competition. Core operations remain clearly profitable, with solid operating margins for a large pharma company. However, reported earnings at the bottom line are very volatile, swinging from solid profits in some years to sizeable losses in others. That pattern strongly suggests the impact of large one‑off charges, write‑downs, or deal-related accounting rather than a collapse in the core franchise. For readers, the key point is that the income statement tells two stories at once: a healthy, growing operating engine layered with occasional heavy accounting hits that can mask that strength in headline net income and earnings per share.

Balance Sheet

Balance Sheet The balance sheet shows a large, asset‑rich business, but one that carries a meaningful debt load. Total assets have drifted down from earlier years, while shareholder equity has shrunk, pointing to a combination of charges, buybacks, and payouts that reduce the cushion for investors. Debt is substantial and has crept up again recently, leaving the company more leveraged than it was a few years ago. Cash on hand is solid but small compared with total borrowings, so the company leans on its strong cash generation rather than a very large cash pile for financial flexibility. Overall, the balance sheet is workable but not conservative, and the level of debt is a key item to monitor over time.

Cash Flow

Cash Flow Cash generation is a clear strength. Operating cash flow has been consistently strong and has generally trended upward, even in years when reported profits dipped into the red. Capital spending needs are relatively modest, so most of the cash generated from the business flows through to free cash flow. This gives the company room to service debt, fund R&D, support dividends and buybacks, and still invest in new opportunities. The big picture: the cash flow statement looks much healthier and more stable than the income statement headlines, underlining the resilience of the underlying franchises.

Competitive Edge

Competitive Edge Bristol‑Myers Squibb, strengthened by the Celgene acquisition, sits among the global leaders in branded pharmaceuticals. It holds powerful positions in oncology, hematology, immunology, and cardiovascular disease, backed by a broad portfolio of blockbuster drugs and a deep patent estate. Scale advantages in research, manufacturing, and commercialization support this position and make it harder for smaller rivals to compete head‑to‑head. At the same time, the company faces the usual big‑pharma challenges: patent expiries on key products, pricing pressure, and intense competition from other innovators and generics. Its moat is meaningful but must be actively defended through continuous innovation and lifecycle management of existing brands.

Innovation and R&D

Innovation and R&D Innovation is at the heart of the Bristol‑Myers/Celgene combination. The group is now a leader in several cutting‑edge areas: cell therapies such as CAR‑T for blood cancers, protein degradation technologies that can tackle previously “undruggable” targets, and advanced immunology and immuno‑oncology platforms. The pipeline includes next‑generation cell therapies, combination cancer regimens, and new approaches in cardiovascular and immune‑mediated diseases. This focus comes with high execution risk—late‑stage failures or regulatory setbacks can be costly—but it also provides the main counterweight to upcoming patent cliffs. In short, the R&D engine is a major strategic asset, and its ability to convert scientific promise into commercial drugs will heavily shape future growth.

Summary

Putting it together, Bristol‑Myers Squibb (which absorbed Celgene and whose CVRs under the CELG‑RI label have expired worthless) shows a mix of operational strength and financial complexity. The business generates steady revenue growth and robust cash flow, anchored by a portfolio of important therapies in cancer, blood disorders, immune disease, and heart health. Reported earnings are noisy, distorted at times by sizable one‑off charges, which can make results look worse than the underlying cash economics. The balance sheet supports operations but carries notable leverage, so debt management and ongoing cash generation are important watchpoints. Competitively, the company benefits from scale, patents, and a rich pipeline, but faces the usual big‑pharma risks: patent expirations, regulatory uncertainty, and scientific execution. Future outcomes will hinge on how well it turns its innovation platforms—especially in cell therapy and protein degradation—into the next wave of durable, high‑value drugs.